drugset / Trial / NCT03844906

A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects

NCT03844906

Phase 1 Completed 40 enrolled Supernus Pharmaceuticals, Inc.
RandomizedCrossoverQuadruple-blindBasic science

Summary

This study is a Phase 1, randomized, double-blind, placebo-controlled study of multiple doses of SAGE-718 using ketamine challenge to evaluate the electrophysiology, safety, tolerability, and pharmacokinetics in healthy subjects.

Timeline

Start
2018-12-27
Primary completion
2019-03-18
Completion
2019-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalzanemdor Small molecule
Background Ketamine Small molecule

Indications

No indication recorded.